Results 41 to 50 of about 2,610,836 (314)

Metastatic Prostate Cancer Synchronous with Male Breast Papillary Ductal Carcinoma in situ: Management Dilemma and Literature Review

Case Reports in Oncology, 2021
Prostate cancer is common in men, but tumour of the male breast is rare. For these two tumours to be presented synchronously in a male patient is even rarer.
H. H. Hasbullah, Farah Wahida MdYusof, Amirah Hayati Ahmad, O. Alzallal, S. E. T. T Sharif   +4 more
semanticscholar   +1 more source

Ductal carcinoma in situ: to treat or not to treat, that is the question

British Journal of Cancer, 2019
Ductal carcinoma in situ (DCIS) now represents 20–25% of all ‘breast cancers’ consequent upon detection by population-based breast cancer screening programmes.
M. Seijen, E. Lips, A. Thompson, S. Nik-Zainal, A. Futreal, E. Hwang, E. Verschuur, J. Lane, J. Jonkers, D. Rea, J. Wesseling, J. Wesseling, Precision team   +12 more
semanticscholar   +1 more source

The Baader-Meinhof phenomenon in ductal carcinoma in situ of the breast [PDF]

, 2016
Sir: We read with interest the review of Pang et al. published in the annual review issue of Histopathology in January 2016, entitled ‘Ductal carcinoma in situ—update on risk assessment and management’, wherein a concise overview of the diagnosis and ...
Floris, Giuseppe, Lambein, Kathleen, Libbrecht, Louis, Van Bockstal, Mieke   +3 more
core   +2 more sources

Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast

medRxiv, 2020
In a substantial number of patients, ductal carcinoma in situ (DCIS) of the breast will never progress to invasive ductal carcinoma, and these patients are often overtreated under the current clinical criteria.
Satoi Nagasawa, Yuta Kuze, I. Maeda, Y. Kojima, A. Motoyoshi, T. Onishi, T. Iwatani, Takamichi Yokoe, J. Koike, M. Chosokabe, Manabu Kubota, Hibiki Seino, A. Suzuki, Masahide Seki, K. Tsuchihara, Eisuke Inoue, K. Tsugawa, T. Ohta, Yutaka Suzuki   +18 more
semanticscholar   +1 more source

Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?

Current Oncology, 2023
Ductal carcinoma in situ (DCIS), especially in the era of mammographic screening, is a commonly diagnosed breast tumor. Despite the low breast cancer mortality risk, management with breast conserving surgery (BCS) and radiotherapy (RT) is the prevailing ...
Ezra Hahn, Danielle Rodin, Rinku Sutradhar, Sharon Nofech-Mozes, Sabina Trebinjac, Lawrence Frank Paszat, Eileen Rakovitch   +6 more
doaj   +1 more source

Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ

Annals of Surgical Oncology, 2016
PurposeControversy exists regarding the optimal negative margin width for ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole-breast irradiation.MethodsA multidisciplinary consensus panel used a meta-analysis of margin width ...
M. Morrow, K. V. Van Zee, L. Solin, N. Houssami, M. Chávez-MacGregor, Jay R Harris, J. Horton, Shelley Hwang, Peggy L. Johnson, M. Marinovich, S. Schnitt, Irene Wapnir, Meena S. Moran   +12 more
semanticscholar   +1 more source

Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions. [PDF]

, 2016
Ductal carcinoma in situ (DCIS) of the breast is a lesion characterized by significant heterogeneity, in terms of morphology, immunohistochemical staining, molecular signatures, and clinical expression.
Bombonati, Alessandro, Mardekian, Stacey K., Palazzo, Juan P.   +2 more
core   +3 more sources

Four‐Dimensional Machine Learning Radiomics for the Pretreatment Assessment of Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy in Dynamic Contrast‐Enhanced MRI

Journal of Magnetic Resonance Imaging, Volume 57, Issue 1, Page 97-110, January 2023., 2023
Background Breast cancer response to neoadjuvant chemotherapy (NAC) is typically evaluated through the assessment of tumor size reduction after a few cycles of NAC. In case of treatment ineffectiveness, this results in the patient suffering potentially severe secondary effects without achieving any actual benefit. Purpose To identify patients achieving
Marco Caballo, Wendelien B. G. Sanderink, Luyi Han, Yuan Gao, Alexandra Athanasiou, Ritse M. Mann   +5 more
wiley   +1 more source

Readmissions and complications in breast ductal carcinoma in situ: A retrospective study comparing screen- and non-screen-detected patients

Women's Health, 2020
Objective: Population-wide mammographic screening programs aim to reduce breast cancer mortality. However, a broad view of the harms and benefits of these programs is necessary to favor informed decisions, especially in the earliest stages of the disease.
Julieta Politi, María Sala, Laia Domingo, María Vernet-Tomas, Marta Román, Francesc Macià, Xavier Castells   +6 more
doaj   +1 more source

Detecting Invasive Ductal Carcinoma with Semi-Supervised Conditional GANs [PDF]

Proceedings of the Future Technologies Conference (FTC) 2020, vol. 3, pp.113-120, 2019
Invasive ductal carcinoma (IDC) comprises nearly 80% of all breast cancers. The detection of IDC is a necessary preprocessing step in determining the aggressiveness of the cancer, determining treatment protocols, and predicting patient outcomes, and is usually performed manually by an expert pathologist.
arxiv   +1 more source